Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Feb 20, 2023 2:40am
168 Views
Post# 35294799

RE:RE:RE:RE:RE:ASCO Presentation - 28% CR at 450 Days

RE:RE:RE:RE:RE:ASCO Presentation - 28% CR at 450 Days

Eoganacht wrote: Two months ago Ferring Pharmaceuticals received FDA approval for Adstiladrin for high-risk, BCG-unresponsive NMIBC based on a CR rate at 12 months of 23.5%. Today Theralase announced to a symposium of genitourinary oncologists a CR rate at 15 months of 28% for the same indication. TLD1433 pdt has higher efficacy, a more enduring response, and better results are likely on the way.

On May 1 Theralase will be presenting updated (and very likely better) results to the 20,000 member AUA, (the American Urology Association). 

Up to now TLD1433 pdt has not been part of the public conversation among urologists with respect to NMIBC options. I think that's about to change. Also, IMHO, FDA approval is on it's way.

 

To add....viral-vector gene therapies are certainly not harmless & they come with a hefty monetary & physical price....in the Adstiladrin trial, 34% of patients had interruptions in their treatments due to adverse reactions.  It is also a drug that should not be taken by those who are immunosuppressed.  

I believe their reported 23.5% durable response (DR) does reflect the percentage of patients who maintained a CR for at least 12 months.  Nonetheless, it is significantly below our current DR, which as you said, should improve based on our data trends using the optimized protocol.

Excited for our day at the upcoming AUA meeting...I consider it a day of enlightenment for many uro-oncologists who still have no clue there's a better/patient-friendly option on the horizon...all imo.  Good luck.

<< Previous
Bullboard Posts
Next >>